Catalyst Calendar
Scope

Thu, Jul 9, 2026

1 updates
INAB
8:00 AM

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard

Trial Results • Phase 1in8bio.com

Wed, Jun 3, 2026

1 updates

Mon, Jun 1, 2026

1 updates
INAB
8:30 AM

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell

Presentation / Abstract • Phase 2ASCO presentation Mon, Jun 1, 2026in8bio.com

Thu, May 14, 2026

1 updates

Thu, May 7, 2026

2 updates
INAB
4:30 PM

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026 Hosting R&D Day on May

Presentation / Abstract • Phase 2in8bio.com

Wed, May 6, 2026

2 updates